- Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)Lu, S.; Zhang, Y.; Zhang, G.; Zhou, J.; Cang, S.; Cheng, Y.; Wu, G.; Cao, P.; Lv, D.; Jian, H.; Chen, C.; Jin, X.; Tian, P.; Wang, K.; Jiang, G.; Chen, G.; Chen, Q.; Zhao, H.; Ding, C.; Ding, L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Furmonertinib versus gefitinib in treatment-naive EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG)Shi, Y-K.; Chen, G.; Wang, X.; Liu, Y.; Wu, L.; Hao, Y.; Liu, C.; Zhu, S.; Zhang, X.; Li, Y.; Liu, J.; Cao, L.; Cheng, Y.; Zhao, H.; Zhang, S.; Zang, A.; Cui, J.; Feng, J.; Liu, F.; Gu, C.被引 3
- Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 studyShi, Yuankai; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Ai-min; Cui, Jiuwei; Feng, Jian; Yang, Nong; Hu, JieAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III study
14阅读
